AT177 / Adial - LARVOL DELTA

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis (GlobeNewswire) - "Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027."

Commercial • First-in-human • New trial • Preclinical • Ulcerative Colitis

Adial Pharmaceuticals Targets H1 2027 IND And H2 2027 Phase 1a Start For Ulcerative Colitis Drug AT177 (Pulse 2.0) - "AT177 is currently undergoing IND-enabling studies as Adial works through the preclinical and chemistry, manufacturing and controls activities required to support the planned regulatory filing....Adial’s immediate execution priorities now center on completing AT177’s preclinical work, advancing CMC activities and assembling the regulatory package needed for the planned IND filing."

IND • New P1 trial • Ulcerative Colitis

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing (GlobeNewswire) - "Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027...Concurrent with the acquisition, Adial entered into a definitive agreement for a concurrent private placement of up to $64 million in gross proceeds to Adial, before deducting placement agent and other offering expenses."

M&A • Ulcerative Colitis